MET amplification has been described in 1–6% of newly diagnosed NSCLC tumors and constitutes a frequent mechanism of acquired resistance in EGFR‐mutant (EGFR‐mut) NSCLC patients treated with tyrosine kinase inhibitors (TKI) [5]. The gene discussed is MET; the disease is non-small cell lung carcinoma.